Akeega (niraparib and abiraterone acetate) — CareFirst (Caremark)

metastatic castration‑resistant prostate cancer (mCRPC) with deleterious or suspected deleterious BRCA‑mutated (BRCAm) disease

Initial criteria

member has a diagnosis of metastatic castration‑resistant prostate cancer
disease has deleterious or suspected deleterious BRCA mutation confirmed by laboratory report
member has had a bilateral orchiectomy OR will be using the requested medication in combination with a luteinizing hormone‑releasing hormone (LHRH) agonist (e.g., goserelin, leuprolide) or antagonist (e.g., degarelix, relugolix)
requested medication will be used in combination with prednisone

member is requesting reauthorization for an indication listed in the coverage criteria
no evidence of unacceptable toxicity
no evidence of disease progression while on the current regimen

12 months